Mild Cognitive ImpairmentPRISEMNCT05845918
PRogram to Improve Stress-levels and Enhance Memory
A study testing PRISEM Remote in people with Mild Cognitive Impairment, run by Emory University at 2 sites in United States.
Trial summary
This is a pilot study with the objective to examine if an in-person and a remote multi-component intervention program can improve chronic stress, vascular measures, and executive function among African American and White patients with Mild Cognitive Impairment. Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Mild Cognitive Impairment
- What is being tested?
- PRISEM Remote
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 2 sitesUnited States
- Study dates
- 21 Feb 2023to 1 May 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age: 50 years or older
- Fluency in English
- African American or White
- MCI will be defined as subjective memory complaints with a Montreal Cognitive Assessment (MoCA) 19- 25
- Prior diagnosis of MCI
- Participants would be sedentary at baseline (self-report of <30 minutes of structured physical activity <3 times per week in the last 6 months) and have poor Mediterranean-Dietary Approaches to Stop Hypertension (DASH) Intervention for Neurodegenerative Delay (MIND) diet scores (using the MIND diet screener)
Who cannot join
- Dementia diagnosis or reversible causes of dementia (e.g., if the patient has hypothyroidism or low vitamin B12 that is contributing to the subject's cognitive impairment)
- Active medical or psychiatric diseases that in the judgment of the investigator would affect the safety of the subject or scientific integrity of the study (e.g., actively manic patient)
- Uncontrolled medical conditions, such as congestive heart failure, reflected by poor exercise tolerance and shortness of breath
- Any physical ailment, such as stroke with residual impairment, that is a barrier to performing study procedures and attending sessions
- History of brain lesions, stroke, or major head trauma in the past year
- Those who are unable to demonstrate that they understood the details of the study (i.e., lack of decisional- capacity to consent) or linguistic limitations
- Pregnant women, prisoners, and adults unable to consent
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Emory Goizueta Alzheimer's Disease Research Center (GADRC)
Atlanta, Georgia, 30329
Emory Dunwoody Clinic
Atlanta, Georgia, 30338
About this study
This is a pilot study with the objective to examine if an in-person and a remote multi-component intervention program can improve chronic stress, vascular measures, and executive function among African American and White patients with Mild Cognitive Impairment. Researchers plan to enroll 45 participants with over-recruitment of African American patients. Participants will be recruited to participate in PRogram to Improve Stress-levels and Enhance Memory (PRISEM) (i.e., remote lifestyle intervention program). The participants will be asked to participate in group-based and/or individual activities that focus on improving health education, nutrition, physical activity, cognitive health, stress levels, and overall well-being. The duration of the study for all participants will be 12 months with 3 study visits. At each study visit, the following measures will be assessed: psychosocial, behavioral, vascular/physical, and executive function.
Read the detailed description
More than half the patients with Mild Cognitive Impairment (MCI), a transitional state between normal aging and dementia, will develop dementia within five years. Despite the clinical and public health significance of MCI, there are no known pharmacological treatment strategies preventing the progression to Alzheimer's Disease (AD). Disappointing results from clinical trials of AD-modifying interventions have increased efforts to focus on prevention strategies that delay the onset of the disease. Since AD-related pathology begins more than a decade before patients develop symptoms, prevention efforts are likely to be more effective when targeted earlier in life. Data is even more limited on higher-risk groups, such as African Americans, who have double the incidence compared with Whites.
This study plans to enroll a diverse population with an over-enrollment of African Americans because African Americans have a higher risk of developing mild cognitive impairment (MCI) and double the incidence of Alzheimer's Disease (AD) compared with Whites. Unfortunately, the prevention and management of MCI have been understudied among African Americans. Chronic stress (such as perceived discrimination and daily environmental stress) in African Americans can affect cognition and plays a role in the worsening of unhealthy behaviors such as smoking, improper diet, and physical inactivity.
Recent studies have predicted that a 10-25% reduction in seven key modifiable risk factors, including behavioral and lifestyle choices, could prevent 1.3 million AD cases globally. Healthy lifestyle approaches can reduce oxidative stress, produce structural and functional changes in the brain, and also influence the rate of neurogenesis in adult and senescent animal models. However, interventions that improve these have often been disappointing, in part because the impact of each lifestyle behavior on AD risk is relatively small.
This pilot study aims to evaluate how a remote multicomponent lifestyle intervention program improves mood symptoms (chronic stress) and positively impacts biomarkers of vascular health and the autonomic nervous system among forty African American and White patients with MCI.
- Conditions
- Mild Cognitive Impairment
- Being tested
- PRISEM Remote
- Keywords
- lifestyle intervention, Chronic Stress
- Medical subject headings
- Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PRISEM RemoteBehavioural
Participants will attend 1-hour sessions weekly for 12 weeks (12 sessions) then biweekly for 8 weeks (4 sessions) and 1 session in the last month (1 session). Sessions will be group-based and will cover the following topics: 1) Program Overview, 2) Get Active, 3)Track Activity, 4) Eating Well, 5) Track Food, 6) Get More Active, 7) Energy In, Energy Out, 8) Eating to Support Health Goals, 9) Manage Stress, 10) Eat Well Away From Home, 11) Managing Triggers, 12) How to Stay Active, 13) Take Charge of Thoughts, 14) Get Back on Track, 15) Get Support (from friends and family), and 16) Staying Motivated. Sessions will include a brief presentation of the topic, followed by an introduction to tools and strategies to practice. This is a facilitated program with participants "driving" the direction and acting as peer support to one another.
| Study group | Role | What they receive |
|---|---|---|
| PRISEM Remote | Experimental | PRISEM Remote is a remote-based lifestyle intervention program in which participants will attend 17 core online sessions via Zoom from the evidence-based Diabetes Prevention Program curriculum with remaining post-core sessions to reinforce strategies and activities introduced in the core program for the duration of 6 months. Receives: Behavioral: PRISEM Remote |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility for the PRISEM pilot to collect additional stress and vascular measurements
Feasibility will be calculated as the percentage of participants who agree to participate and are enrolled according to the target, with a loss to follow-up.
Measured: 6 months
Acceptability for the PRISEM pilot to collect additional stress and vascular measures.
Acceptability of the PRISEM pilot participants will be assessed using semi-structured interviews regarding vascular and stress measures conducted over the course of the study.
Measured: Baseline, 6 months, and 12 months
Secondary outcomes (16)
Perceived Stress Scale (PSS) score
The questions in the PSS ask about feelings and thoughts during the last month. In each case, respondents are asked how often they felt a certain way. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 \& 4 = 0) to the four positively stated items (items 4, 5, 7, \& 8) and then summing across all 10 scale items. Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress.
Measured: Baseline, 6 months, and 12 months
Short Form (SF)-12 Quality of Life (QoL) score
The SF-12 QoL uses two items each to estimate scores for four to eight health concepts (physical functioning, role-physical, role-emotional, and mental health). Scores for the remaining four health concepts (bodily, pain, general health, vitality, and social functioning) are estimated using one item each. The lower the score the more disability.
Measured: Baseline, 6 months, and 12 months
Weight
Self-reported weight (Kg) will be collected at each study time point
Measured: Baseline and 6 months
Body Mass Index (BMI)
Body Mass Index (BMI) is a person's weight in kilograms divided by the square of height in meters. BMI will be calculated at each study time point.
Measured: Baseline and 6 months
Systolic and diastolic blood pressure (BP) measurements
Systolic and diastolic blood pressure (SBP and DBP)will be measured at each time point. BP (mmHg) will be assessed by utilizing an automatic sphygmomanometer in which a cuff will be placed on the participant's forearm.
Measured: Baseline and 6 months
Heart rate variability (HRV).
Heart rate variability (HRV) will be measured with an ECG monitor. A validated signal processing code will be used to evaluate these signals for noise and detect the necessary ECG component measures, and when outliers are suspected, a visual inspection will be performed. If any episodes of Atrial fibrillation are detected by the program, they will be confirmed by the study team and excluded. HRV will be examined in 5-minute sliding windows, and the median, 10th percentile, and minimum values will be calculated.
Measured: Baseline and 6 months
Pulse Wave Analysis.
Indices of arterial stiffness and wave reflections will be estimated in the supine position using the Sphygmocor device (Atcor Medical, Australia), which records sequential high-quality pressure waveforms at peripheral pulse sites using a high-fidelity tonometer. Pulse-wave velocity (PWV) measured between carotid and femoral arteries is a regional assessment of aortic stiffness and is the gold standard index of arterial stiffness.
Measured: Baseline and 6 months
Trail Making Test (TMT) Part A
The TMT is a measure of attention, speed, and mental flexibility. It also tests spatial organization, visual pursuits, recall, and recognition. Part A requires the individual to draw lines to connect 25 encircled numbers distributed on a page. Part A tests visual scanning, numeric sequencing, and visuomotor speed. A score over 78 seconds may indicate a deficit in visual perception. The average time is around 29 seconds.
Measured: Baseline, 6 months, and 12 months
Trail Making Test (TMT) Part B
Trail Making Test (TMT) Part B is scored based on the time in seconds it takes to complete the task, which involves alternating between connecting numbered and lettered circles in ascending order (1-A-2-B-3-C). Part B assesses cognitive flexibility and executive function, and is scored separately from Part A. A higher score indicates greater cognitive impairment.
Measured: Baseline, 6 months, and 12 months
Flanker Test
The Flanker test measures inhibitory control and attention by having participants identify a central stimulus (fish or arrows) while ignoring flanking stimuli. Scoring is based on both accuracy and reaction time. If a participant's accuracy is below 80% correct, the score is based solely on accuracy. If accuracy is 80% or higher, both accuracy and reaction time are used to calculate the score. This ensures participants who are accurate but slow, or fast but inaccurate, are scored accordingly. The final computed score is converted to an age-adjusted scale score. A score of 100 represents the national average for a given age, with 115 being one standard deviation above average and 85 being one standard deviation below average.
Measured: Baseline, 6 months, and 12 months
Pattern Comparison Processing Speed Test (PCPST)
PCPST is an assessment of processing speed. Participants are asked to quickly determine whether two stimuli are the same or not the same. It measures how quickly a person can decide if two visual patterns are identical, scoring how many correct comparisons are made in a set time. Scores are converted to normative scores that compare performance to a representative sample, with a higher score indicating better processing speed. A mean of 100 with a standard deviation of 15 is considered average, with scores indicating the test-taker's performance relative to their age group or the general population.
Measured: Baseline, 6 months, and 12 months
Picture Sequence Memory (PSM) test
The Picture Sequence Memory (PSM) test, specifically the NIH Toolbox version, is scored by counting the number of adjacent pairs of pictures correctly placed in the sequence across three learning trials. The meaning of the score is that it provides a measure of episodic memory, which is the ability to recall and place in order a series of events or images. A higher score indicates better episodic memory performance, while lower scores suggest memory impairments.
Measured: Baseline, 6 months, and 12 months
List Sorting Working Memory Test scores
The List Sorting Working Memory Test scores are calculated based on the number of stimuli correctly recalled and sequenced in order of size. The test has two phases: a one-dimensional phase (1-List) and a two-dimensional phase (2-List). A higher score indicates better working memory, meaning an individual can better register, maintain, and manipulate visual and auditory information.
Measured: Baseline, 6 months, and 12 months
Dimensional Change Card Sort (DCCS)
The Dimensional Change Card Sort (DCCS) measures cognitive flexibility by assessing how well a person can switch between different sorting rules. It typically involves sorting cards by one rule (e.g., color) and then switching to a new rule (e.g., shape). The test records how many cards are correctly sorted and how long it takes to respond. Pass/Fail: The primary scoring method is a pass/fail based on performance after the rule-switching "switch" trials.
Measured: Baseline, 6 months, and 12 months
Physical Activity Scale for the Elderly (PASE)
The PASE score (Physical Activity Scale for the Elderly) is a numerical value derived from a 12-item questionnaire that measures the physical activity level of older adults over the past week. Meaning is determined by the score, with higher scores indicating greater physical activity. Scores are calculated by multiplying the frequency, duration, and intensity of various activities (leisure, household, occupational) by pre-determined weights and summing them up, resulting in a score that can range from 0 to 400 or more.
Interpreting scores: Sedentary: 0-40; Light Physical Activity: 41-90; Moderate to Intense Activity: 91+
Measured: Baseline and 6 months
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet Quiz
The MIND diet quiz is a 15-point assessment of how closely participants' diet aligns with the MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) eating plan. The final score, which ranges from 0 to 15, indicates their level of adherence and is associated with their potential for better cognitive health. Higher scores (above 9): Indicate they are following the MIND diet closely.
Moderate scores (7 and 8): Suggest a moderate alignment with the MIND diet. Even moderate adherence has been shown to provide a reduced risk of Alzheimer's compared to the lowest scores.
Lower scores (below 6): Indicate that their diet is less aligned with the brain-healthy principles of the MIND diet.
Measured: Baseline, 6 months, and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2023
- Study start21 Feb 2023
- Primary completion22 Sep 2025
- Study completion1 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mild Cognitive ImpairmentStudies of the same condition, open and under way.
- More trials run by Emory UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 45 participants (actual)
Sponsor and investigators
- Lead sponsor
- Emory University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Responsible party
- Principal investigator, Ambar Kulshreshtha, Emory University
- Investigators
- Ambar Kulshreshtha, MD, PhD, Principal investigator, Emory University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05845918
- Sponsor's protocol ID
- STUDY00004811
- Other IDs
- 1K23AG066931-01A1, 2025P011143
- Acronym
- PRISEM
- Status last verified
- May 2026
- First submitted
- 27 Mar 2023
- Last updated
- 28 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The investigators will share deidentified individual participant data that underlie published articles.
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PRogram to Improve Stress-levels and Enhance Memory
- ClinicalTrials.gov ID
- NCT05845918
- Acronym / sponsor ID
- PRISEM / STUDY00004811
- Conditions
- Mild Cognitive Impairment
- Keywords
- lifestyle intervention, Chronic Stress
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 45 participants (actual)
- Lead sponsor
- Emory UniversityUniversity, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Study start
- 21 Feb 2023 (actual)
- Primary completion
- 22 Sep 2025 (actual)
- Study completion
- 1 May 2026 (actual)
- First posted
- 6 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a pilot study with the objective to examine if an in-person and a remote multi-component intervention program can improve chronic stress, vascular measures, and executive function among African American and White patients with Mild Cognitive Impairment. Researchers plan to enroll 45 participants with over-recruitment of African American patients. Participants will be recruited to participate in PRogram to Improve Stress-levels and Enhance Memory (PRISEM) (i.e., remote lifestyle intervention program). The participants will be asked to participate in group-based and/or individual activities that focus on improving health education, nutrition, physical activity, cognitive health, stress levels, and overall well-being. The duration of the study for all participants will be 12 months with 3 study visits. At each study visit, the following measures will be assessed: psychosocial, behavioral, vascular/physical, and executive function.
Detailed description
More than half the patients with Mild Cognitive Impairment (MCI), a transitional state between normal aging and dementia, will develop dementia within five years. Despite the clinical and public health significance of MCI, there are no known pharmacological treatment strategies preventing the progression to Alzheimer's Disease (AD). Disappointing results from clinical trials of AD-modifying interventions have increased efforts to focus on prevention strategies that delay the onset of the disease. Since AD-related pathology begins more than a decade before patients develop symptoms, prevention efforts are likely to be more effective when targeted earlier in life. Data is even more limited on higher-risk groups, such as African Americans, who have double the incidence compared with Whites.
This study plans to enroll a diverse population with an over-enrollment of African Americans because African Americans have a higher risk of developing mild cognitive impairment (MCI) and double the incidence of Alzheimer's Disease (AD) compared with Whites. Unfortunately, the prevention and management of MCI have been understudied among African Americans. Chronic stress (such as perceived discrimination and daily environmental stress) in African Americans can affect cognition and plays a role in the worsening of unhealthy behaviors such as smoking, improper diet, and physical inactivity.
Recent studies have predicted that a 10-25% reduction in seven key modifiable risk factors, including behavioral and lifestyle choices, could prevent 1.3 million AD cases globally. Healthy lifestyle approaches can reduce oxidative stress, produce structural and functional changes in the brain, and also influence the rate of neurogenesis in adult and senescent animal models. However, interventions that improve these have often been disappointing, in part because the impact of each lifestyle behavior on AD risk is relatively small.
This pilot study aims to evaluate how a remote multicomponent lifestyle intervention program improves mood symptoms (chronic stress) and positively impacts biomarkers of vascular health and the autonomic nervous system among forty African American and White patients with MCI.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| PRISEM Remote | Experimental | Behavioral: PRISEM RemotePRISEM Remote is a remote-based lifestyle intervention program in which participants will attend 17 core online sessions via Zoom from the evidence-based Diabetes Prevention Program curriculum with remaining post-core sessions to reinforce strategies and activities introduced in the core program for the duration of 6 months. |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age: 50 years or older
- Fluency in English
- African American or White
- MCI will be defined as subjective memory complaints with a Montreal Cognitive Assessment (MoCA) 19- 25
- Prior diagnosis of MCI
Key exclusion criteria (7 listed)
- Dementia diagnosis or reversible causes of dementia (e.g., if the patient has hypothyroidism or low vitamin B12 that is contributing to the subject's cognitive impairment)
- Active medical or psychiatric diseases that in the judgment of the investigator would affect the safety of the subject or scientific integrity of the study (e.g., actively manic patient)
- Uncontrolled medical conditions, such as congestive heart failure, reflected by poor exercise tolerance and shortness of breath
- Any physical ailment, such as stroke with residual impairment, that is a barrier to performing study procedures and attending sessions
- History of brain lesions, stroke, or major head trauma in the past year
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PRISEM RemoteParticipants will attend 1-hour sessions weekly for 12 weeks (12 sessions) then biweekly for 8 weeks (4 sessions) and 1 session in the last month (1 session). Sessions will be group-based and will cover the following topics: 1) Program Overview, 2) Get Active, 3)Track Activity, 4) Eating Well, 5) Track Food, 6) Get More Active, 7) Energy In, Energy Out, 8) Eating to Support Health Goals, 9) Manage Stress, 10) Eat Well Away From Home, 11) Managing Triggers, 12) How to Stay Active, 13) Take Charge of Thoughts, 14) Get Back on Track, 15) Get Support (from friends and family), and 16) Staying Motivated. Sessions will include a brief presentation of the topic, followed by an introduction to tools and strategies to practice. This is a facilitated program with participants "driving" the direction and acting as peer support to one another. | Behavioural | PRISEM Remote |
Primary outcome
Feasibility for the PRISEM pilot to collect additional stress and vascular measurements
Time frame: 6 months
Feasibility will be calculated as the percentage of participants who agree to participate and are enrolled according to the target, with a loss to follow-up.
Acceptability for the PRISEM pilot to collect additional stress and vascular measures.
Time frame: Baseline, 6 months, and 12 months
Acceptability of the PRISEM pilot participants will be assessed using semi-structured interviews regarding vascular and stress measures conducted over the course of the study.
16 secondary outcomes
Perceived Stress Scale (PSS) score
Time frame: Baseline, 6 months, and 12 months
Short Form (SF)-12 Quality of Life (QoL) score
Time frame: Baseline, 6 months, and 12 months
Weight
Time frame: Baseline and 6 months
Body Mass Index (BMI)
Time frame: Baseline and 6 months
Systolic and diastolic blood pressure (BP) measurements
Time frame: Baseline and 6 months
Heart rate variability (HRV).
Time frame: Baseline and 6 months
Pulse Wave Analysis.
Time frame: Baseline and 6 months
Trail Making Test (TMT) Part A
Time frame: Baseline, 6 months, and 12 months
Trail Making Test (TMT) Part B
Time frame: Baseline, 6 months, and 12 months
Flanker Test
Time frame: Baseline, 6 months, and 12 months
Pattern Comparison Processing Speed Test (PCPST)
Time frame: Baseline, 6 months, and 12 months
Picture Sequence Memory (PSM) test
Time frame: Baseline, 6 months, and 12 months
List Sorting Working Memory Test scores
Time frame: Baseline, 6 months, and 12 months
Dimensional Change Card Sort (DCCS)
Time frame: Baseline, 6 months, and 12 months
Physical Activity Scale for the Elderly (PASE)
Time frame: Baseline and 6 months
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet Quiz
Time frame: Baseline, 6 months, and 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2026.
- Individual participant dataSharing planned: Yes. The investigators will share deidentified individual participant data that underlie published articles.
Related trials for Mild Cognitive Impairment
Enrolling by invitationPhase 2
Tau PET Outcomes With Anti-amyloid Immunotherapies
Cognitive Impairment, Mild, Dementia, Mild
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingPhase 1
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Alzheimer Disease
Recruiting
Non-invasive Brain Stimulation for the Treatment of Mild Cognitive Impairment in Parkinson's Disease
Parkinson Disease, Mild Cognitive Impairment
RecruitingObservational study
Loneliness as Risk Factor for Dementia
Mild Cognitive Impairment (MCI), Dementia (Diagnosis)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ambar Kulshreshtha, MD, PhD principal investigator
Emory University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PRISEM Remote in people with Mild Cognitive Impairment, run by Emory University at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility for the PRISEM pilot to collect additional stress and vascular measurements (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2026.